3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
24
Triple Negative Breast Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Diseases
4
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Lung Neoplasms
3
Lung Diseases
3
Bronchial Neoplasms
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Kidney Neoplasms
2
Endocrine Gland Neoplasms
2
Digestive System Neoplasms
2
Breast Neoplasms, Male
2
Wilms Tumor
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thymoma
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Sarcoma, Kaposi
1
Interventions
selpercatinib
2
exemestane
1
entinostat
1
alectinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
entinostat
×
Breast
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled